2017 Position Statement on the Use of Follow-On Biologics and Biosimilars for Endocrine Diseases

ASEM 文献综述

Official American Association of Clinical Endocrinology document (2017) on “2017 Position Statement on the Use of Follow-On Biologics and Biosimilars for Endocrine Diseases”. This position statement provides guidance on follow-on biologics versus biosimilars, interchangeability and substitution, FDA draft guidance for interchangeability of biosimilars, and clinical application. DOI: 10.4158/EP-2017-0052.

此摘要有助于您识别文档。对于临床建议，请始终查阅官方现行版本及其更新日期。